Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Progress on early detection of Alzheimer’s disease

Written by | 19 Jun 2022

Inside the body, some seemingly harmless proteins have sinister potential. In the case of Alzheimer’s disease, the amyloid-beta (Aβ) protein, which is vital for brain growth, can become… read more.

Mental disorders linked to subsequent dementia

Written by | 2 Mar 2022

A decades-long New Zealand national data base study suggests an association between mental disorders and subsequent dementia. The findings were published on February 16, 2022 in JAMA Psychiatry…. read more.

Update on the phase IV confirmatory study of Aduhelm for Alzheimer’s disease – Biogen + Eisai

Written by | 31 Jan 2022

Biogen Inc. and Eisai Co., Ltd. provided an important update on the continuing progress of the Phase IV post-marketing confirmatory study of Aduhelm (aducanumab-avwa) 100 mg/mL injection for… read more.

Neuroprotective mechanism altered by Alzheimer’s disease risk genes

Written by | 5 Jan 2022

The brain has a natural protective mechanism against Alzheimer’s disease, and researchers at Baylor College of Medicine, Texas Children’s Hospital and collaborating institutions have discovered that gene variants… read more.

Leaking calcium in neurons an early sign of Alzheimer’s pathology

Written by | 7 Nov 2021

Alzheimer’s disease is known for its slow attack on neurons crucial to memory and cognition. But why are these particular neurons in aging brains so susceptible to the… read more.

Early accumulation of tau in the brain predicts memory decline in Alzheimer’s disease

Written by | 10 Oct 2021

Over 50 million people around the world suffer from dementia. Alzheimer’s disease is the most common form of dementia and is characterised by an accumulation of the proteins… read more.

More effective treatment of Alzheimer’s

Written by | 4 Oct 2021

Researchers at Uppsala University have designed new antibodies that might provide more effective treatment methods for Alzheimer’s disease. By designing antibodies that bind even to the smaller aggregates,… read more.

Research reveals drug targets for memory enhancement

Written by | 30 Sep 2021

Loss of memory is a core feature of many neurological and psychiatric disorders including Alzheimer’s disease and schizophrenia. Current treatment options for memory loss are very limited and… read more.

An open letter to the Alzheimer’s disease community from Biogen Head of Research and Development, Alfred Sandrock, M.D., Ph.D

Written by | 27 Jul 2021

Statement from Head of Research and Development, Alfred Sandrock, M.D., Ph.D.:Biogen Inc. – On June 7, 2021, Aduhelm became the first approved treatment to address a defining pathology… read more.

FDA grants accelerated approval for Aduhelm to treat Alzheimer’s disease – Biogen + Eisai

Written by | 15 Jun 2021

Biogen and Eisai, Co., Ltd. announced that the FDA has granted accelerated approval for Aduhelm (aducanumab-avwa) as the first and only Alzheimer’sdisease treatment to address a defining pathology… read more.

Rejuvenating’ the Alzheimer’s brain

Written by | 8 Jun 2021

Alzheimer’s disease is the main cause of dementia and current therapeutic strategies cannot prevent, slow down or cure the pathology. The disease is characterized by memory loss, caused… read more.

New research finds exercise may help slow memory loss for people living with Alzheimer’s dementia

Written by | 4 Mar 2021

PHOENIX, Arizona, February 26, 2021- Promising new research shows aerobic exercise may help slow memory loss for older adults living with Alzheimer’s dementia.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.